ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma

Authors
Publication date
1 October 2018
Publisher

Abstract

Experimentele farmacotherapi

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Leiden University Scholary Publications

    redirect
    oaioai:scholarlypublications.univ...
    Last time updated on 12/03/2021